1. Introduction {#sec1}
===============

Bladder cancer (BC) is the seventh most prevalent cancer worldwide and results in significant morbidity and mortality. In the United States, BC is the fourth most common cancer in males and the ninth in females with an estimated 70,980 new cases and 14,330 deaths in 2009 \[[@B1]\]. Muscle-invasive BC (MIBC) accounts for virtually all the mortality from bladder cancer and represents more than a quarter (≈25--40%) of all BC. MIBC spreads from the bladder in a predictable stepwise manner to the lymph nodes and then to visceral organs. Metastatic BC is incurable and invariably fatal. For patients with MIBC, radical cystectomy (RC) with pelvic lymphadenectomy (PLND) represents the mainstay of therapy. The PLND during RC represents both a chance to accurately stage the cancer as well as a chance to remove all the cancer from the body. An extended PLND may have prognostic and therapeutic benefits. However, there is still debate regarding the boundaries of adequate PLND during RC. In this paper, we will define the state of art regarding the extent of PLND and nodal prognostic factors and their effect on oncological outcomes of BC patients.

2. Lymphatic Drainage of the Bladder {#sec2}
====================================

The anatomy of lymphatic drainage of the urinary bladder is critically important for definition of the boundaries for an adequate PLND during RC. The bladder lymphatic drainage has well-defined origin from lymphatic plexus within its wall, in the submucosa and extending into the muscles. Lymphatic channels drain through anterior, lateral, and posterior intercalated lymph nodes (LNs) located within the perivesical fat. Efferent lymphatics then drain to the external iliac, obturator, internal iliac, and presacral LNs. Lymphatic trunks leading from the pelvic LNs subsequently drain into more proximal common iliac LNs and then to aortocaval LNs \[[@B2], [@B3]\]. Skip lesions have been reported, but their rarity suggests that the pelvic LNs are the primary landing site and that metastasis occurs in an orderly progression \[[@B2], [@B4]--[@B8]\].

3. Surgical Boundaries of the Lymphadenectomy {#sec3}
=============================================

[Figure 1](#fig1){ref-type="fig"} shows the template of extended PLND during RC. Extended PLND include LNs between the aortic bifurcation and common iliac vessels (proximally), the genitofemoral nerve (laterally), the circumflex iliac vein and LN of Cloquet (distally), and the internal iliac vessels (posteriorly), including the obturator fossa and the presacral LNs anterior to the sacral promontory. An extended dissection may also extend superiorly to the level of the inferior mesenteric artery. Importantly, the PLND along the external iliac vessels is completely circumferential while the proximal dissection along the common iliac and great vessels includes anterior and lateral nodal tissues \[[@B5], [@B7], [@B9]\]. Standard PLND differs in its cranial boundary which is limited to the level of the common iliac bifurcation. A limited PLND involves the lymph nodes in the obturator fossa.

4. Incidence of Lymph Node Metastasis {#sec4}
=====================================

The incidence of positive LNs in RC specimens is between 18--30% as shown in [Table 1](#tab1){ref-type="table"}. Predictably, the incidence of LN involvement correlates with T stage, grade, and presence of lympho vascular invasion (LVI) \[[@B5], [@B10], [@B11]\]. [Table 2](#tab2){ref-type="table"} shows the correlation with stage in the largest RC series. The incidence of LN metastasis is ≤5% for \<T2, around 25% in T2, and 40--45% in T3/T4 BC.

5. Lymphadenectomy: Staging/Prognostic Benefits {#sec5}
===============================================

Precise staging of LN status is an important clinico-pathological prognostic parameter following RC. Nodal involvement identifies a high-risk group that has the worst oncological outcomes and may benefit from adjuvant systemic therapies. Clearly, extending the field of PLND will increase the number of LNs removed and the chances of identifying positive nodes \[[@B5], [@B14], [@B13], [@B12]\]. Vazina et al. found 16% patients with T3/T4 disease to have LN metastasis proximal to the boundaries of standard PLND and 30% of patients with common iliac LN involvement also had involvement of presacral LNs \[[@B10]\]. Steven and Poulsen found 34.4% of positive LNs above the common iliac bifurcation \[[@B13]\]. An inadequately performed PLND may underestimate the true disease burden and underestimate the need for potentially therapeutic adjuvant therapies. An accurate PLND represents the best way to accurately stage patients with MIBC.

6. Lymphadenectomy: Therapeutic Benefits {#sec6}
========================================

Removal of involved lymph nodes theoretically can improve survival as it decreases overall tumor burden and allows the immune system and chemotherapeutics to target a smaller number of cancer cells, potentially with greater efficacy. Indeed, recent retrospective and prospective nonrandomized studies suggest a better oncological outcome from removing more LNs via an extended PLND during RC. Proponents for extended PLND note frequent involvement of nodes outside the standard PLND templates \[[@B10], [@B13], [@B15]\]. Some studies found more proximal LN metastases above the cranial boundary of the standard PLND (≈20%) where common iliac, presacral, and LNs above the aortic bifurcation were involved in 15--23%, 6--8%, and 4--10%, respectively \[[@B3], [@B5]\]. Additionally, up to 50% of patients with limited LN involvement can be rendered disease-free after extended PLND \[[@B2], [@B5]\]. The benefits of PLND in removing micrometastatic disease appear to be significant in BC. Extended PLND requires an additional time but does not add significantly to the morbidity of the procedure \[[@B2], [@B16]--[@B18]\]. However, there are other studies that did not find an advantage for extended PLND \[[@B6], [@B7], [@B11]\]. The difference between these studies may reflect the selection criteria for the patients. Further, while the removal of grossly negative but microscopically involved LN may have a therapeutic benefit, the removal of bulky involved LN is unlikely to improve survival. The level of PLND remains controversial and can only be determined by well-designed carefully controlled prospective randomized studies.

7. Therapeutic Benefits in Node Negative Bladder Cancer {#sec7}
=======================================================

The extent of PLND may act as a surrogate marker for overall surgical quality and survival benefits from PLND in node negative patients during RC were reported \[[@B22], [@B21], [@B23], [@B19], [@B20]\]. A thorough extended PLND might decrease positive surgical margins, and, hence improve the oncological outcome. The 5-year RFS with organ-confined tumors was 85% with an extended dissection compared to 64% with similar pathology undergoing a more limited PLND \[[@B23]\]. We recommend an extended PLND, whenever possible; even in clinically node negative patients.

8. Nodal Prognostic Factors {#sec8}
===========================

The prognosis in patients with lymph node-positive disease can be stratified by the stage of the primary bladder tumor, extent of PLND, the number of lymph nodes removed, the number of LNs involved (tumor burden), LN density, and the presence of nodal extracapsular extension. We would like to highlight the most commonly studied nodal prognostic factors.

8.1. Number of Lymph Nodes Removed {#sec8.1}
----------------------------------

The median nodal counts reported from RC series is considerably variable and ranges from 9 to 30 ([Table 3](#tab3){ref-type="table"}). This number has been used as a surrogate marker for the adequacy of PLND. A standard PLND yields an average of 8--14 nodes while extending PLND up to the aortic bifurcation often yields 25--45 nodes \[[@B2], [@B23], [@B15]\]. Different studies suggested different cut point for the number of LNs that should be removed to achieve adequate PLND ([Table 4](#tab4){ref-type="table"}). SEER data showed that PLND and the number of LNs removed are variable, and dissection of at least 10 to 14 nodes during RC is the most important prognostic factor \[[@B24]\]. The number of LNs removed not only suggests the completeness of the PLND, but may have prognostic significance in both LN positive and negative patients \[[@B3], [@B22]\]. Koppie et al. could not find a minimum number of LNs to be sufficient for optimal oncological outcomes. Instead, the probability of survival continued to increase as the number of LNs removed increases \[[@B25]\].

Unfortunately, with the striking interinstitution and intrainstitution variability in node counts and variability within patients, it is hard to define an exact minimum number of LNs to be removed. The same extended PLND may yield 20 or 80 LN depending on the patient, exposure to chemotherapy, surgical technique, institution at which performed, pathologist examining the LNs, and protocol used to evaluate LNs number. Thus, a cutoff of 30 would render the same extended PLND inadequate or adequate. We believe that the extent of PLND is more important marker for better surgical quality, and, finally, oncological outcome until pathologic processing and aforementioned variables can be addressed.

8.2. Lymph Node Yield {#sec8.2}
---------------------

Many factors might explain the variability in node yield. Clinical, anatomical, pathological, surgical, and institutional factors may play a role \[[@B2], [@B4]\]. Old age and associated comorbidities may hinder extended PLND \[[@B2], [@B26]\]. There might be some anatomic variability in the number of nodes present in different individuals \[[@B4]\]. Tumor stage may be associated with nodal yield \[[@B2], [@B4], [@B20]\]. On the other hand, negative margin status has been associated with higher nodal yield \[[@B4], [@B27]\]. Recent BCG or neoadjuvant chemotherapy might have an effect, probably by causing inflammation and fibrosis thus helping more nodal yield \[[@B4]\]. Sending LNs in separate packages was reported to increase the nodal yield \[[@B21], [@B15]\]. The method of pathologic evaluation including the use of fat-clearing solutions may play a role as well \[[@B2], [@B4]\]. While there were contradictory reports about the effect of surgeon volume on LN yield \[[@B4], [@B27]\], academic or teaching hospitals with a higher RC volume tend to report higher LN counts \[[@B4], [@B27], [@B28]\]. Recently, Fang et al. implement a policy that at least 16 LNs has to be examined pathologically. They showed that implementation of this policy can improve the survival due to increased awareness to perform a more thorough PLND \[[@B29]\].

8.3. Number of Positive Nodes (Tumor Burden) {#sec8.3}
--------------------------------------------

The number of positive LNs (tumor burden) is an important prognostic factor following RC \[[@B3], [@B7], [@B22], [@B21], [@B30]\]. Recurrence and survival are inversely related to an increasing number of positive LNs. Some studies reported the absolute number of LNs involved as an independent prognostic factor. Others defined cutoff numbers for worse prognosis \[[@B24]\]. Herr et al. determined a cut-off of 4 positive LNs \[[@B20]\], Steven and Poulsen detrmined 5 positive LNS \[[@B13]\], and Stein et al. showed significantly worse survival in patients with \>8 metastatic LNs \[[@B30]\]. Furthermore, the study from Mansoura showed a significance difference in prognosis when stratifying positive LNs (1 versus 2--5 versus 5) \[[@B11]\]. This was also the case in a population-based study from the SEER database (1 versus 2 versus 3 versus \>3) \[[@B31]\]. Collectively, It is obvious that larger tumor burden in LNs is associated with poor oncological outcomes. Further, bulky positive LNs are invariably associated with a poor prognosis \[[@B32]\].

9. The Concept of "Lymph Node Density" {#sec9}
======================================

The LN density could be a useful prognostic concept because it combines the extent of PLND as indicated by the total number of LNs removed and the tumor burden as indicated by the number of positive nodes. Herr and Stein were the first to introduce the concept of LN density (number of positive nodes/number of removed nodes) with a cutoff of 20% to stratify outcomes \[[@B30], [@B33]\]. [Table 5](#tab5){ref-type="table"} describes the cut-off values suggested for LN density in different studies and the oncological outcomes based on these cut-off values. A pooled analysis of MD Anderson and Memorial Sloan-Kettering Cancer Centers showed that LN density is superior to TNM nodal status in predicting oncological outcomes after RC \[[@B17]\]. Nevertheless, this index can be useful only if there is a standard number of nodes that have to be removed and a standard level of PLND. Certainly, a LN density of 20% based on 1 positive LN out of 5 LNs removed is different than 20% based on 8 positive out of 40 LNs. Perhaps, this is the reason why there has not been widespread clinical use of this parameter since its introduction in 2003.

10. Extracapsular Extension of Lymph Node Metastasis {#sec10}
====================================================

Extracapsular extension (perforation of the capsule of LN by tumor tissue with extranodal growth) has recently been shown to double the risk of recurrence when compared to intranodal confined LN metastasis. Fleischman et al. evaluated 101 patients who underwent RC and extended PLND for LN+ disease and analyzed the influence of extracapsular extension (found in 58% of the patients) on patient prognoses. Patients with extracapsular extension had a significantly decreased recurrence free survival (RFS) (median, 12 versus 60 months, *P* \< .001) and overall survival (OS) (median, 16 versus 60 months, *P* \< .001) compared with those with intranodal metastases. Multivariate analyses confirmed that extracapsular extension of LN metastases was the strongest negative predictor for RFS \[[@B34]\]. However, others did not find a significant association between extracapsular extension and survival after RC, leading to issue of whether this pathological finding is really of importance \[[@B35]\].

11. The Concept of "Sentinel Lymph Node" {#sec11}
========================================

The sentinel node is defined as the initial site of lymphatic drainage from a primary tumor. Determination of sentinel node for BC should be on individualized basis rather than on anatomic location of primary tumor due to the variability of lymphatic drainage \[[@B4]\]. Ghoneim and Abol-Enein introduced the concept of sentinel region (intrapelvic LNs) rather than sentinel node \[[@B6], [@B7]\]. Involvement of the intrapelvic LNs may be the first step in nodal metastasis in most BCs and skip lesions might be very rare \[[@B38], [@B27], [@B26], [@B35]--[@B41]\]. However, higher number of patients and longer followup is needed before widespread practice is accepted.

Recently, Studer group used multimodality technique to locate the primary lymphatic landing sites of the bladder. Their technique counted upon cystoscopic-guided injection of technetium nanocolloid followed by preoperative radioactive LN detection with SPECT/CT followed by intraoperative verification with gamma probe. They found that limited pelvic PLND removed only about 50% of all primary lymphatic landing sites while extending the PLND up to the ureteroiliac crossing removed 90% \[[@B8]\]. Analysis of their study proves that the template or extent of PLND is more important than merely the number of LNs removed \[[@B36]\]. The concept of sentinel node remains investigational in BC. If sentinel nodes could be accurately identified on individual basis, this could guide the decision about the extent of PLND. Although, extended PLND can be safely and routinely performed with minimal additional morbidity, we do not currently see a need to compromise outcomes of patients with BC with a suboptimal nodal dissection and reliance on frozen section analyses.

12. A Tailored Approach to Lymphadenectomy {#sec12}
==========================================

Tailoring PLND based on the clinical stage, so that patients with advanced tumors or evidence of nodal involvement would be treated with an extended PLND, whereas those with organ-confined disease and no evidence of nodal involvement would undergo standard PLND, has been advocated. However, the use of clinical stage of the primary tumor for determining of the extent of PLND is problematic \[[@B19]\]. Understaging could happen in approximately half of patients with clinically organ-confined disease \[[@B19], [@B37]\]. Intraoperative finding including inspection and palpation of more proximal lymphatic regions may miss a substantial percentage of positive LNs \[[@B19]\]. If the morbidity of PLND is minimal, then there should be minimal downside to the use of an extended PLND in all patients. Currently, there are no reliable models to guide the decision regarding the extent of PLND.

13. Morbidity of Lymphadenectomy {#sec13}
================================

Early complications of 28% and perioperative mortality rates of 2.6--3% have been reported in large RC series \[[@B21], [@B38]\]. An extended PLND may prolong operative time by about 60 minutes. However, it does not appear to increase morbidity or mortality compared to the standard approach \[[@B2], [@B16]--[@B18]\]. Comparing LN positive versus LN negative cases, extended versus standard PLND confirmed that there are no significant differences in morbidity or mortality \[[@B2], [@B16]--[@B18], [@B30]\]. Extended PLND is a safe option in experienced hands that may improve oncological outcomes by decreasing positive surgical margins and resection of undetected micrometastases \[[@B17], [@B19]\]. Despite that the administration of neoadjuvant radiation or chemotherapy before RC may not increase the morbidity and mortality. Patients who have received these treatments should be judged carefully before performing an extended PLND, as there might be a higher risk of complications \[[@B9], [@B16], [@B17]\].

14. Laparoscopic-/Robotic-Assisted Surgery {#sec14}
==========================================

Laparoscopic-/robotic-assisted RC and PLND were reported as safe feasible procedures with acceptable nodal yield and potentially equivalent oncological outcomes to open RC with no added morbidities \[[@B39], [@B40]\]. Complete removal of the LN-bearing tissue up to aortic bifurcation or inferior mesenteric artery is more challenging using minimally invasive modalities. Recently, extended PLND has been demonstrated with the robotic system, with comparable LN yields \[[@B41], [@B42], [@B43]\].

We believe that without long-term functional and oncologic outcome data, laparoscopic- and robotic-assisted RC should be considered investigative techniques, and patients chosen for these modalities should be appropriately selected and counseled.

15. Future Directions {#sec15}
=====================

Many of the controversies regarding the extent and the utility of PLND in RC stem from the fact that data in support or against their use have been obtained from retrospective analyses of databases and trials. As such none of these studies were powered to answer the questions regarding the utility of PLND in RC. A multicenter prospective randomized clinical trial is in the final stages of approval by SWOG (PI: Seth Lerner, Baylor College of Medicine), and it randomizes patients to standard versus extended lymphadenectomy during RC for bladder cancer. The trial is powered to detect differences in survival and when completed may truly establish the role of PLND on the outcomes of patients with bladder cancer.

16. Conclusions {#sec16}
===============

The incidence of nodal disease in BC is around 25% and is influenced by other pathological factors, most importantly the pT stage. Extended PLND may provide prognostic and therapeutic advantages in both LN-positive and negative patients without significantly increasing morbidity. However, the extent of PLND during RC needs better definition through prospective randomized studies with long-term followup. Laparoscopic-/robotic-assisted RC and PLND are still new modalities that need longer evaluation before recommending for more patients.
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![Template of extended lymph node dissection during radical cystectomy.](IJSO2011-758189.001){#fig1}

###### 

Incidence of lymph node metastasis in radical cystectomy.

  References                       Year   No. of patients   No. of LN metastasis   (%) of LN metastasis
  -------------------------------- ------ ----------------- ---------------------- ----------------------
  Vieweg et al. \[[@B44]\]         1999   682               193                    28.1
  Leissner et al. \[[@B22]\]       2000   447               136                    30.4
  Herr and Donat \[[@B45]\]        2001   763               193                    25.3
  Stein et al. \[[@B21]\]          2001   1,054             246                    23.3
  Gschwend et al. \[[@B46]\]       2002   686               193                    28.1
  Madersbacher et al. \[[@B47]\]   2003   507               121                    23.9
  Vazina et al. \[[@B10]\]         2004   176               43                     24.4
  Leissner et al. \[[@B5]\]        2004   290               81                     27.9
  Abdel-Latif et al. \[[@B11]\]    2004   418               110                    26.3
  Nishiyama et al. \[[@B48]\]      2004   1,113             162                    14.6
  Fleischmann et al. \[[@B34]\]    2005   507               124                    24.5
  Hautmann et al. \[[@B49]\]       2006   788               142                    18.0
  Shariat et al. \[[@B50]\]        2006   833               198                    23.8
  Koppie et al. \[[@B25]\]         2006   1,110             243                    21.9
  Stein et al. \[[@B14]\]          2007   1,621             383                    23.6
  Steven and Poulsen \[[@B13]\]    2007   336               64                     19.0
  Wright et al. \[[@B31]\]         2007   5,201             1260                   24.3
  Ghoneim et al. \[[@B38]\]        2008   2,720             555                    20.4
  Osawa et al. \[[@B51]\]          2009   435               83                     19.1
  Bruins et al. \[[@B52]\]         2009   1,600             369                    23.1
  Stephenson et al. \[[@B32]\]     2010   763               178                    23.3
  Seiler et al. \[[@B53]\]         2010   840               162                    19.3

###### 

Correlation of pathological T stage with LN metastases.

  Study                   Poulsen et al. \[[@B23]\]   Viewg et al. \[[@B44]\]   Stein et al. \[[@B21]\]   Madersbacher et al. \[[@B47]\]   Leissner et al. \[[@B5]\]   Vazina et al. \[[@B10]\]   Abdel-Latif et al. \[[@B11]\]   Hautmann et al. \[[@B49]\]   Ghoneim and Abol-Enein \[[@B54]\]
  ----------------------- --------------------------- ------------------------- ------------------------- -------------------------------- --------------------------- -------------------------- ------------------------------- ---------------------------- -----------------------------------
  Year                    1998                        1999                      2001                      2003                             2004                        2004                       2004                            2006                         2008
  period                  1990--1997                  1980--1990                1971--1997                1985--2000                       1999--2002                  1992--2002                 1997--1999                      1986--2003                   1971--2000
  Total no. of patients   191                         686                       1054                      507                              290                         176                        418                             788                          2720
                                                                                                                                                                                                                                                               
                          \% of LN metastasis                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                               
  pT0, pTis, and pT1      3                           10                        5                         2                                2                           4                          4                               1                            2
  pT2a                    18                          9                         18                        17                               13                          16                         7                               10                           8
  T2b                     25                          23                        27                        34                               22                          40                         25                              41                           19
  pT3                     51                          43                        45                        41                               44                          50                         48                              44                           39
  pT4                     44                          41                        45                                                         50                                                     65                                                           36
                                                                                                                                                                                                                                                               
  Total                   26                          28                        23                        24                               28                          24                         26                              18                           20

###### 

Median number of lymph nodes removed in cystectomy series.

  References                       Year   No. of patients            Median number of LNs removed (range)
  -------------------------------- ------ -------------------------- --------------------------------------
  Stein et al. \[[@B30]\]          2003   244                        30 (1--96)
  Herr \[[@B33]\]                  2003   162                        13 (2--32)
  Kassouf et al. \[[@B55]\]        2006   108                        12 (1--58)
  Kassouf et al. \[[@B56]\]        2008   248                        12 (2--58)
  Fleischmann et al. \[[@B57]\]    2005   101                        22 (10--43)
  Wright et al. \[[@B31]\]         2008   1260                       9 (1--75)
  Steven et al. \[[@B13]\]         2007   64                         27 (11--49)
  Abdel--Latif et al. \[[@B11]\]   2004   110                        18 (mean)
  Lerner et al. \[[@B58]\]         1993   132                        31 (3--96)
  Leissner et al. \[[@B22]\]       2000   302                        15 (1--46)
  Herr et al. \[[@B27]\]           2004   268                        10 (0--54)
  Koppie et al. \[[@B25]\]         2006   1042                       9 (0--53)
  Poulsen et al. \[[@B23]\]        1998   117                        25 (9--67) extended
  Dhar et al. \[[@B59]\]           2008   336 (Cleveland Clinic)     22 (10--43) extended
                                          322 (University of Bern)   

###### 

Suggested number of LNs to be removed to achieve better oncological outcomes.

  References                      Year   No. of patients   Median number of LNs removed (range)   Cut-off number of LNs to be removed
  ------------------------------- ------ ----------------- -------------------------------------- -------------------------------------
  Stein et al. \[[@B30]\]         2003   244               30 (1--96)                             15
  Konety et al. \[[@B60]\]        2003   361               N/A                                    10--14
  Herr \[[@B33]\]                 2003   162               13 (2--32)                             13
  Kassouf et al. \[[@B56]\]       2008   248               12 (2--58)                             12
  Fleischmann et al. \[[@B57]\]   2005   101               22 (10--43)                            5
  Wright et al. \[[@B31]\]        2008   1260              9 (1--75)                              10
  Leissner et al. \[[@B22]\]      2000   302               15 (1--46)                             16
  Herr et al. \[[@B27]\]          2004   268               10 (0--54)                             10
  Herr et al. \[[@B20]\]          2002   322               8 (0--44) for N0                       8 for N0
                                                           11 (1--25) for N+                      11 for N+
  Fang et al. \[[@B29]\]          2010   349               17 (0--53)                             16
  Dangle et al. \[[@B12]\]        2010   120               37 (11--87)                            23--27
  Shirotake et al. \[[@B61]\]     2010   169               10 for N0                              9 for N0
                                                           13 for N+                              

###### 

Cut-off lymph node densities and their effect upon oncological outcomes.

  References                       Year   No. of patients   Median number of LNs removed (range)   Cut-off PLND   5-Y survival rates   
  -------------------------------- ------ ----------------- -------------------------------------- -------------- -------------------- ------
  Stein et al. \[[@B30]\]          2003   244               30 (1--96)                             20             17                   44
  Herr \[[@B33]\]                  2003   162               13 (2--32)                             20             8\*                  64\*
  Kassouf et al. \[[@B55]\]        2006   108               12 (1--58)                             25             11                   38
  Kassouf et al. \[[@B56]\]        2008   248               12 (2--58)                             20             15\*                 55\*
  Fleischmann et al. \[[@B57]\]    2005   101               22 (10--43)                            20             15                   41
  Steven and Poulsen \[[@B13]\]    2007   64                27 (11--49)                            20             25                   47
  Abdel--Latif et al. \[[@B11]\]   2004   110               18 (mean)                              20             16                   39
  Wiesner et al. \[[@B62]\]        2009   152               33 (15--77)                            11             8\*                  34\*
  Osawa et al. \[[@B51]\]          2009   435               12 (1--80)                             25             12\*                 51\*

All studies reported RFS except \*reported CSS.
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